AbbVie And FutureGen Biopharmaceutical Announce License Agreement To Develop FG-M701; Abbvie To Receive Exclusive Global License, FutureGen To Receive $150M Upfront Payment And Up To $1.56B In Milestones
AbbVie And FutureGen Biopharmaceutical Announce License Agreement To Develop FG-M701; Abbvie To Receive Exclusive Global License, FutureGen To Receive $150M Upfront Payment And Up To $1.56B In Milestones
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.